The Manufacturers Life Insurance Company Has $2.27 Million Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

The Manufacturers Life Insurance Company lifted its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 40.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 299,152 shares of the biotechnology company's stock after purchasing an additional 86,571 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.14% of BioCryst Pharmaceuticals worth $2,274,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Deerfield Management Company L.P. Series C raised its position in shares of BioCryst Pharmaceuticals by 62.9% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company's stock worth $50,279,000 after purchasing an additional 3,140,804 shares during the period. Fisher Asset Management LLC increased its position in BioCryst Pharmaceuticals by 16.9% in the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company's stock valued at $25,369,000 after acquiring an additional 481,359 shares during the period. Rice Hall James & Associates LLC increased its position in BioCryst Pharmaceuticals by 4.0% in the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company's stock valued at $16,444,000 after acquiring an additional 84,102 shares during the period. Charles Schwab Investment Management Inc. increased its position in BioCryst Pharmaceuticals by 5.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,887,994 shares of the biotechnology company's stock valued at $14,349,000 after acquiring an additional 102,860 shares during the period. Finally, Cubist Systematic Strategies LLC increased its position in BioCryst Pharmaceuticals by 528.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 1,112,232 shares of the biotechnology company's stock valued at $6,874,000 after acquiring an additional 935,132 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on BCRX. Royal Bank of Canada restated an "outperform" rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Needham & Company LLC restated a "buy" rating and issued a $14.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Finally, Barclays lifted their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an "equal weight" rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $15.60.

BioCryst Pharmaceuticals Stock Performance

Shares of BioCryst Pharmaceuticals stock traded up $0.12 during midday trading on Monday, hitting $7.73. The company's stock had a trading volume of 1,434,073 shares, compared to its average volume of 2,875,893. The stock has a 50-day simple moving average of $7.58 and a 200-day simple moving average of $7.35. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The business had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. The business's quarterly revenue was up 35.1% on a year-over-year basis. During the same period last year, the business earned ($0.19) EPS. On average, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.